Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Lara Goldstein

Freedom Biosciences Gets $10.5M In Seed Financing For Psychedelics Research, This Is What We Know

Freedom Biosciences achieved a major $10.5 million in a seed financing round in which MBX Capital, PsyMed Ventures, Village Global and The Yale Startup, among others, participated.

The clinical-stage biotech company, which develops therapeutics based on various psychedelics to treat major depressive disorder, will use the funds to advance its lead ketamine program as well as other exploratory programs under the leadership of cofounder Dr. John Krystal, who presides over the psychiatry department at Yale University. Krystal has extensive experience working with ketamine for depression treatment.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.